Back to top
more

Alkermes (ALKS)

(Delayed Data from NSDQ)

$24.38 USD

24.38
1,611,692

+0.23 (0.95%)

Updated May 20, 2024 04:00 PM ET

After-Market: $24.38 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value B Growth D Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (86 out of 249)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

ALXN or ALKS: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

ALXN vs. ALKS: Which Stock Is the Better Value Option?

Alkermes (ALKS) Reports Narrower-Than-Expected Loss in Q1

by Zacks Equity Research

Alkermes (ALKS) reports narrower-than-expected loss and sales beat in the first quarter of 2019.

GILD vs. ALKS: Which Stock Is the Better Value Option?

by Zacks Equity Research

GILD vs. ALKS: Which Stock Is the Better Value Option?

Earnings Preview: Alkermes (ALKS) Q1 Earnings Expected to Decline

by Zacks Equity Research

Alkermes (ALKS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Alkermes Reports Positive Data From Schizophrenia Study

by Zacks Equity Research

Alkermes (ALKS) reports positive top-line data from phase IIIb study evaluating Aristada and Invega Sustenna in patients with acute exacerbations of schizophrenia.

Recro Pharma Falls as FDA Denies Approval to Pain Candidate

by Zacks Equity Research

FDA issues complete response letter for Recro Pharma's (REPH) marketing application for pain candidate, meloxicam, for the second time.

Alkermes Focuses on Pipeline, Depends on Partners for Funds

by Zacks Equity Research

Alkermes (ALKS) has an impressive pipeline and is focused on the development of its candidates.

Why Is Alkermes (ALKS) Up 4.7% Since Last Earnings Report?

by Zacks Equity Research

Alkermes (ALKS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Allergan's Depression Candidate Fails in Studies, Stock Down

by Zacks Equity Research

Allergan's (AGN) three acute pivotal studies on depression candidate, rapastinel, fail to meet their primary endpoint. Stocks declines 1.9%

Biotech Stock Roundup: ONCE, CMTA Soar on Merger News, Other Pipeline Updates

by Zacks Equity Research

Key highlights of the past week are merger agreements, and regulatory and pipeline developments.

Alkermes' (ALKS) and Biogen's NDA for BIIB098 Accepted by FDA

by Zacks Equity Research

The FDA accepts Alkermes (ALKS) and partner Biogen's NDA for diroximel fumarate and sets an action date in the fourth quarter of 2019.

The Zacks Analyst Blog Highlights: Intercept, Gilead, Vertex, Alkermes and Clovis

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Intercept, Gilead, Vertex, Alkermes and Clovis

Biotech Stock Roundup: ICPT Strong on NASH Drug Data, Collaborations & More

by Zacks Equity Research

Key highlights of the past week are regulatory and pipeline developments along with research collaboration deals.

Alkermes (ALKS) Q4 Earnings & Revenues Surpass Estimates

by Zacks Equity Research

Alkermes' (ALKS) earnings and sales exceed estimates in the fourth quarter of 2018.

Alkermes (ALKS) Q4 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Alkermes (ALKS) delivered earnings and revenue surprises of 666.67% and 24.84%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?

The Zacks Analyst Blog Highlights: Gilead, Vertex, Celgene, Alkermes and AVEO

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Gilead, Vertex, Celgene, Alkermes and AVEO

Analysts Estimate Alkermes (ALKS) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Alkermes (ALKS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Biotech Stock Roundup: Celgene Tops in Q4, Gilead Disappoints, ALKS & AVEO Sink

by Zacks Equity Research

Key highlights of the week were the fourth-quarter results by biotech bigwigs Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX) and Celgene (CELG).

Alkermes Sinks as FDA Refuses to Approve Depression Drug

by Zacks Equity Research

Alkermes (ALKS) falls almost 5% on a Complete Response Letter from the FDA for its pipeline candidate, ALKS 5461for major depressive disorder (MDD).

What Makes Alkermes (ALKS) a New Buy Stock

by Zacks Equity Research

Alkermes (ALKS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

CBM or ALKS: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

CBM vs. ALKS: Which Stock Is the Better Value Option?

Biogen Begins Improved Dosing Regimen on Tysabri in Phase III

by Zacks Equity Research

Biogen (BIIB) commences enrollment in late-stage study to evaluate an expanded interval dosing of its MS drug, Tysabri, in patients with relapsing MS.

    Alkermes, Biogen Submit NDA to FDA for Multiple Sclerosis Drug

    by Zacks Equity Research

    Alkermes (ALKS) and Biogen submit an NDA to the FDA for diroximel fumarate (BIIB098), being developed for the treatment of relapsing forms of MS.

    Alkermes (ALKS) Down 14.2% Since Last Earnings Report: Can It Rebound?

    by Zacks Equity Research

    Alkermes (ALKS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

    Jazz Pharma (JAZZ) Beats on Q3 Earnings, Lowers Sales View

    by Zacks Equity Research

    Jazz Pharmaceuticals (JAZZ) lowers sales guidance for 2018. Stock declines 14% following the release of third-quarter earnings.